Sacrificial Biofabrication for Vascularization: Concept, Materials, Technologies, and Applications
Shi J., Wang C., Mei X., Zhang B., Wu J., Green RA.
Narrative Review, published in Adv Mater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Adv Mater (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40922624
- PMCID
- PMC12783884
- DOI
- 10.1002/adma.202507747
- Citations
- 4
Abstract (original English)
Vasculature plays a crucial role in tissue engineering since it is essential for maintaining tissue viability by efficient nutrient and oxygen exchange as well as waste removal. The creation of biomimetic vascular networks is therefore critical for the development of functional tissue constructs. Sacrificial biofabrication has emerged as an effective method for engineering vascular structures by creating temporary templates that are subsequently removed to form well-defined vascular channels. In this review, the concept of sacrificial biofabrication is introduced and defined, with a focus on vascularization. Then, a comprehensive overview of the commonly used sacrificial materials based on different types of external stimuli is provided, and the classification and design principles of surrounding materials are briefly introduced. Additionally, various fabrication technologies employed to process sacrificial materials are summarized, and the diverse applications of sacrificial biofabrication in disease models and regenerative medicine are discussed. Finally, the current challenges are highlighted, and the future perspectives for advancing sacrificial biofabrication are explored to address the demand for vasculature manufacturing.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.